Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Mar 15;99(6):1361–1366. doi: 10.1172/JCI119295

Plasma lipoprotein(a) levels and expression of the apolipoprotein(a) gene are dependent on the nucleotide polymorphisms in its 5'-flanking region.

K Suzuki 1, M Kuriyama 1, T Saito 1, A Ichinose 1
PMCID: PMC507952  PMID: 9077546

Abstract

The apolipoprotein(a) (apo[a]) gene encodes a protein component of lipoprotein(a) [Lp(a)] whose plasma levels vary widely among individuals. Hyper-Lp(a)-emia constitutes a risk factor for thromboembolic disease. We previously subclassified the apo(a) gene into four allelic types (A-D) by polymorphisms in the 5'-flanking region. To elucidate whether these polymorphisms affect the expression of apo(a), we measured plasma Lp(a) concentrations in vivo by ELISA and examined expression of the gene by an in vitro assay using its 5'-flanking region. Homozygotes of type C had significantly higher Lp(a) levels than those of type D. The relative expression of type C was also about three times higher than that of type D, which was consistent with the in vivo results. Deletion analysis revealed that the substitution of C by T (+93) led to negative regulation in expression of the gene, while the change of G to A (+121) led to positive regulation. These results indicate that the polymorphisms in the 5'-flanking region of the apo(a) gene affect the efficiency of its expression and, in part, play a role in regulating plasma Lp(a) levels.

Full Text

The Full Text of this article is available as a PDF (193.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azrolan N., Gavish D., Breslow J. L. Plasma lipoprotein(a) concentration is controlled by apolipoprotein(a) (apo(a)) protein size and the abundance of hepatic apo(a) mRNA in a cynomolgus monkey model. J Biol Chem. 1991 Jul 25;266(21):13866–13872. [PubMed] [Google Scholar]
  2. BERG K. A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM. Acta Pathol Microbiol Scand. 1963;59:369–382. doi: 10.1111/j.1699-0463.1963.tb01808.x. [DOI] [PubMed] [Google Scholar]
  3. Boerwinkle E., Leffert C. C., Lin J., Lackner C., Chiesa G., Hobbs H. H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992 Jul;90(1):52–60. doi: 10.1172/JCI115855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boerwinkle E., Menzel H. J., Kraft H. G., Utermann G. Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet. 1989 Apr;82(1):73–78. doi: 10.1007/BF00288277. [DOI] [PubMed] [Google Scholar]
  5. Cooke T., Sheahan R., Foley D., Reilly M., D'Arcy G., Jauch W., Gibney M., Gearty G., Crean P., Walsh M. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation. 1994 Apr;89(4):1593–1598. doi: 10.1161/01.cir.89.4.1593. [DOI] [PubMed] [Google Scholar]
  6. Edelberg J. M., Gonzalez-Gronow M., Pizzo S. V. Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. Biochemistry. 1989 Mar 21;28(6):2370–2374. doi: 10.1021/bi00432a004. [DOI] [PubMed] [Google Scholar]
  7. Gavish D., Azrolan N., Breslow J. L. Plasma Ip(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene. J Clin Invest. 1989 Dec;84(6):2021–2027. doi: 10.1172/JCI114395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gaw A., Boerwinkle E., Cohen J. C., Hobbs H. H. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common "null" allele at the apo(a) locus. J Clin Invest. 1994 Jun;93(6):2526–2534. doi: 10.1172/JCI117263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Genest J., Jr, Jenner J. L., McNamara J. R., Ordovas J. M., Silberman S. R., Wilson P. W., Schaefer E. J. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol. 1991 May 15;67(13):1039–1145. doi: 10.1016/0002-9149(91)90862-f. [DOI] [PubMed] [Google Scholar]
  10. Gorman C. M., Moffat L. F., Howard B. H. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol. 1982 Sep;2(9):1044–1051. doi: 10.1128/mcb.2.9.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hall C. V., Jacob P. E., Ringold G. M., Lee F. Expression and regulation of Escherichia coli lacZ gene fusions in mammalian cells. J Mol Appl Genet. 1983;2(1):101–109. [PubMed] [Google Scholar]
  12. Harpel P. C., Gordon B. R., Parker T. S. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A. 1989 May;86(10):3847–3851. doi: 10.1073/pnas.86.10.3847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Henriksson P., Angelin B., Berglund L. Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest. 1992 Apr;89(4):1166–1171. doi: 10.1172/JCI115699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ichinose A. Characterization of the apolipoprotein(a) gene. Biochem Biophys Res Commun. 1995 Apr 6;209(1):365–371. doi: 10.1006/bbrc.1995.1512. [DOI] [PubMed] [Google Scholar]
  15. Ichinose A., Kuriyama M. Detection of polymorphisms in the 5'-flanking region of the gene for apolipoprotein(a). Biochem Biophys Res Commun. 1995 Apr 6;209(1):372–378. doi: 10.1006/bbrc.1995.1513. [DOI] [PubMed] [Google Scholar]
  16. Ichinose A. Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis. Biochemistry. 1992 Mar 31;31(12):3113–3118. doi: 10.1021/bi00127a011. [DOI] [PubMed] [Google Scholar]
  17. Kraft H. G., Köchl S., Menzel H. J., Sandholzer C., Utermann G. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet. 1992 Nov;90(3):220–230. doi: 10.1007/BF00220066. [DOI] [PubMed] [Google Scholar]
  18. Krempler F., Kostner G. M., Bolzano K., Sandhofer F. Turnover of lipoprotein (a) in man. J Clin Invest. 1980 Jun;65(6):1483–1490. doi: 10.1172/JCI109813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Loscalzo J., Weinfeld M., Fless G. M., Scanu A. M. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990 Mar-Apr;10(2):240–245. doi: 10.1161/01.atv.10.2.240. [DOI] [PubMed] [Google Scholar]
  20. Maeda S., Abe A., Seishima M., Makino K., Noma A., Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989 Aug;78(2-3):145–150. doi: 10.1016/0021-9150(89)90218-9. [DOI] [PubMed] [Google Scholar]
  21. McLean J. W., Tomlinson J. E., Kuang W. J., Eaton D. L., Chen E. Y., Fless G. M., Scanu A. M., Lawn R. M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12;330(6144):132–137. doi: 10.1038/330132a0. [DOI] [PubMed] [Google Scholar]
  22. Miles L. A., Plow E. F. Lp(a): an interloper into the fibrinolytic system? Thromb Haemost. 1990 Jun 28;63(3):331–335. [PubMed] [Google Scholar]
  23. Mizokami A., Chang C. Induction of translation by the 5'-untranslated region of human androgen receptor mRNA. J Biol Chem. 1994 Oct 14;269(41):25655–25659. [PubMed] [Google Scholar]
  24. Mooser V., Mancini F. P., Bopp S., Pethö-Schramm A., Guerra R., Boerwinkle E., Müller H. J., Hobbs H. H. Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet. 1995 Feb;4(2):173–181. doi: 10.1093/hmg/4.2.173. [DOI] [PubMed] [Google Scholar]
  25. Murai A., Miyahara T., Fujimoto N., Matsuda M., Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986 Feb;59(2):199–204. doi: 10.1016/0021-9150(86)90048-1. [DOI] [PubMed] [Google Scholar]
  26. Parlavecchia M., Pancaldi A., Taramelli R., Valsania P., Galli L., Pozza G., Chierchia S., Ruotolo G. Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men < 55 years of age. Am J Cardiol. 1994 Aug 15;74(4):346–351. doi: 10.1016/0002-9149(94)90401-4. [DOI] [PubMed] [Google Scholar]
  27. Perombelon Y. F., Soutar A. K., Knight B. L. Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles. J Clin Invest. 1994 Apr;93(4):1481–1492. doi: 10.1172/JCI117126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rader D. J., Cain W., Ikewaki K., Talley G., Zech L. A., Usher D., Brewer H. B., Jr The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 1994 Jun;93(6):2758–2763. doi: 10.1172/JCI117292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rader D. J., Cain W., Zech L. A., Usher D., Brewer H. B., Jr Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest. 1993 Feb;91(2):443–447. doi: 10.1172/JCI116221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rhoads G. G., Dahlen G., Berg K., Morton N. E., Dannenberg A. L. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986 Nov 14;256(18):2540–2544. [PubMed] [Google Scholar]
  31. Rouy D., Koschinsky M. L., Fleury V., Chapman J., Anglés-Cano E. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry. 1992 Jul 14;31(27):6333–6339. doi: 10.1021/bi00142a024. [DOI] [PubMed] [Google Scholar]
  32. Saiki R. K., Gelfand D. H., Stoffel S., Scharf S. J., Higuchi R., Horn G. T., Mullis K. B., Erlich H. A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988 Jan 29;239(4839):487–491. doi: 10.1126/science.2448875. [DOI] [PubMed] [Google Scholar]
  33. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Scanu A. M., Fless G. M. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest. 1990 Jun;85(6):1709–1715. doi: 10.1172/JCI114625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Utermann G. The mysteries of lipoprotein(a). Science. 1989 Nov 17;246(4932):904–910. doi: 10.1126/science.2530631. [DOI] [PubMed] [Google Scholar]
  36. Wade D. P., Clarke J. G., Lindahl G. E., Liu A. C., Zysow B. R., Meer K., Schwartz K., Lawn R. M. 5' control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1369–1373. doi: 10.1073/pnas.90.4.1369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wade D. P., Lindahl G. E., Lawn R. M. Apolipoprotein(a) gene transcription is regulated by liver-enriched trans-acting factor hepatocyte nuclear factor 1 alpha. J Biol Chem. 1994 Aug 5;269(31):19757–19765. [PubMed] [Google Scholar]
  38. Zysow B. R., Lindahl G. E., Wade D. P., Knight B. L., Lawn R. M. C/T polymorphism in the 5' untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol. 1995 Jan;15(1):58–64. doi: 10.1161/01.atv.15.1.58. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES